Exscientia website screenshot

Exscientia

Exscientia was an Oxford UK-based AI-driven precision medicine and drug design company, founded in 2012 as a spin-out from the University of Dundee. Its platform combined generative chemistry (Centaur Chemist) with patient tissue-based screening (EVE, an automated single-cell platform for testing drug candidates directly against patient-derived tumor samples) to design small-molecule drug candidates faster and at lower cost than conventional pharma R&D. Notable firsts included EXS-21546 (an A2A antagonist developed with Evotec), DSP-1181 (the first AI-designed molecule to enter human clinical trials, with Sumitomo Dainippon Pharma), and DSP-0038 (a dual 5-HT1A/5-HT2A modulator for Alzheimer's psychosis). Exscientia maintained active pharma partnerships with Sanofi, Bristol Myers Squibb, Bayer, Sumitomo, and Merck KGaA. Exscientia was acquired by Recursion Pharmaceuticals (NASDAQ: RXRX) in an all-stock deal that closed in November 2024; the combined company operates under the Recursion brand and the legacy exscientia.ai website now redirects to recursion.com. The Exscientia name persists primarily through its GitHub organization, which continues to host open-source scientific Python packages for molecular predictive modelling (molflux), physics-based ML potentials (physicsml), antibody structure prediction (abodybuilder3), and biomolecular simulation (biosimspace) used by the wider computational chemistry and structural biology community. Exscientia did not expose any public commercial APIs, SDKs, or developer products before or after the merger; platform access was always delivered through collaborative drug-discovery agreements.

Exscientia is profiled on the APIs.io network. Tagged areas include Drug Discovery, Drug Design, AI Drug Design, Precision Medicine, and Biotech.

🌐 Visit website 📡 Source on GitHub
3.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-09-08 · rubric v0.20.0
0 APIs
Drug DiscoveryDrug DesignAI Drug DesignPrecision MedicineBiotechPharmaceuticalsGenerative ChemistryCentaur ChemistEVE PlatformPatient-Derived ScreeningOncologySmall MoleculesComputational ChemistryMachine-LearningOpen-SourceAcquired

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-09-08 · rubric v0.20.0
Composite quality — 3.7/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.0 / 17
Access Clarity 0.0 / 17
Operational Transparency 0.3 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 1.1 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Delegated User Identity 0 / 6
Protected Resource Metadata 0 / 5
Registration Without a Human 0 / 6
Agentic Commerce Well-Known Document 0 / 5
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero: never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and several others — scorable at all.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/exscientia: open an issue to ask a question, or submit a pull request to add artifacts. Submit an artifact on GitHub — free → Manage your own listing — the Influence plan, $499/mo →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Exscientia Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Build 1

SDKs, sample code, and the tooling you integrate with

GitHubOrganization
GitHubOrganization

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Company 4

The organization behind the API

Website
Website
 LegacyWebsite
LegacyWebsite
 Crunchbase
Crunchbase
 LinkedIn
LinkedIn

Other 10

Properties that don't map to a standard resource type

AcquisitionAnnouncement
AcquisitionAnnouncement
 AcquisitionClosing
AcquisitionClosing
 ParentCompany
ParentCompany
 Molflux
Molflux
 PhysicsML
PhysicsML
 ABodyBuilder3
ABodyBuilder3
 BioSimSpace
BioSimSpace
 StableNetGuardOwl
StableNetGuardOwl
 RDVC
RDVC
 Wikipedia
Wikipedia

Scroll for all 10

Source (apis.yml)

apis.yml Raw ↑ 
aid: exscientia
name: Exscientia
description: 'Exscientia was an Oxford UK-based AI-driven precision medicine and drug design company, founded in 2012 as a
  spin-out from the University of Dundee. Its platform combined generative chemistry (Centaur Chemist) with patient tissue-based
  screening (EVE, an automated single-cell platform for testing drug candidates directly against patient-derived tumor samples)
  to design small-molecule drug candidates faster and at lower cost than conventional pharma R&D. Notable firsts included
  EXS-21546 (an A2A antagonist developed with Evotec), DSP-1181 (the first AI-designed molecule to enter human clinical trials,
  with Sumitomo Dainippon Pharma), and DSP-0038 (a dual 5-HT1A/5-HT2A modulator for Alzheimer''s psychosis). Exscientia maintained
  active pharma partnerships with Sanofi, Bristol Myers Squibb, Bayer, Sumitomo, and Merck KGaA. Exscientia was acquired by
  Recursion Pharmaceuticals (NASDAQ: RXRX) in an all-stock deal that closed in November 2024; the combined company operates
  under the Recursion brand and the legacy exscientia.ai website now redirects to recursion.com. The Exscientia name persists
  primarily through its GitHub organization, which continues to host open-source scientific Python packages for molecular
  predictive modelling (molflux), physics-based ML potentials (physicsml), antibody structure prediction (abodybuilder3),
  and biomolecular simulation (biosimspace) used by the wider computational chemistry and structural biology community. Exscientia
  did not expose any public commercial APIs, SDKs, or developer products before or after the merger; platform access was always
  delivered through collaborative drug-discovery agreements.'
type: Index
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
position: Producing
access: 3rd-Party
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/exscientia.png
tags:
- Drug Discovery
- Drug Design
- AI Drug Design
- Precision Medicine
- Biotech
- Pharmaceuticals
- Generative Chemistry
- Centaur Chemist
- EVE Platform
- Patient-Derived Screening
- Oncology
- Small Molecules
- Computational Chemistry
- Machine-Learning
- Open-Source
- Acquired
tags_raw:
- Drug Discovery
- Drug Design
- AI Drug Design
- Precision Medicine
- Biotech
- Pharmaceuticals
- Generative Chemistry
- Centaur Chemist
- EVE Platform
- Patient-Derived Screening
- Oncology
- Small Molecules
- Computational Chemistry
- Machine Learning
- Open Source
- Acquired
url: https://raw.githubusercontent.com/api-evangelist/exscientia/refs/heads/main/apis.yml
created: '2026-05-24'
modified: '2026-05-24'
specificationVersion: '0.23'
apis: []
common:
- type: DomainSecurity
  url: security/exscientia-domain-security.yml
- type: Website
  url: https://www.recursion.com
- type: LegacyWebsite
  url: https://www.exscientia.ai
- type: AcquisitionAnnouncement
  url: https://ir.recursion.com/news-releases/news-release-details/recursion-and-exscientia-combine-create-leading-techbio-company
- type: AcquisitionClosing
  url: https://ir.recursion.com/news-releases/news-release-details/recursion-completes-business-combination-exscientia
- type: ParentCompany
  url: https://www.recursion.com
- type: GitHubOrganization
  url: https://github.com/Exscientia
- type: Molflux
  url: https://github.com/Exscientia/molflux
- type: PhysicsML
  url: https://github.com/Exscientia/physicsml
- type: ABodyBuilder3
  url: https://github.com/Exscientia/abodybuilder3
- type: BioSimSpace
  url: https://github.com/Exscientia/biosimspace
- type: StableNetGuardOwl
  url: https://github.com/Exscientia/StableNetGuardOwl
- type: RDVC
  url: https://github.com/Exscientia/rdvc
- type: Wikipedia
  url: https://en.wikipedia.org/wiki/Exscientia
- type: Crunchbase
  url: https://www.crunchbase.com/organization/exscientia
- type: LinkedIn
  url: https://www.linkedin.com/company/exscientialtd
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this
  • find_providersBrowse and filter every provider in the catalog.
  • get_provider_artifactsEvery artifact this provider publishes, grouped by type.
  • get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
  • get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
  • get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
  • get_provider_ratingPRO — composite, band, trend and facet scores.
  • apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
  • resolveTurn a domain, URL or GitHub org into the provider it belongs to.
  • find_cohortsEvery scored population of providers in the catalog.
All 92 tools →

Call it yourself

curl for this page
This provider 
curl "https://apis.io/api/v1/providers/exscientia"
All providers 
curl "https://apis.io/api/v1/providers?limit=25"
Every operation they expose 
curl "https://apis.io/api/v1/providers/exscientia/operations?limit=25"
How their score was established 
curl "https://apis.io/api/v1/providers/exscientia/evidence"

Discovery needs no key. Ratings and market analysis are Pro.

Get an API key

Free tier, no form to fill in. Signing in shares your email address with us — we store it to create your key and to recognise you if you sign in with another provider. See our Privacy Policy and Terms.

GitHub Google LinkedIn

A second provider on the same verified email joins the account you already have.